Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DD36YG
|
|||
| Drug Name |
OP-0595
|
|||
| Synonyms |
Nacubactam; 1452458-86-4; RG6080; RG-6080; UNII-832O37V7MZ; RO7079901; 832O37V7MZ; FPI-1459; 1452458-86-4 (free acid); RO-7079901; (1R,2S,5R)-2-((2-aminoethoxy)carbamoyl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulfate; Nacubactam [INN]; Nacubactam (USAN); Nacubactam [USAN:INN]; CHEMBL3989959; SCHEMBL15206610; SCHEMBL17975933; GTPL10833; MFCD28986228; OP0595; ZINC207610051; DB15353; SB17180; AS-35134; HY-109008; CS-0030506; D11329; Q27269383; (1R,2S,5R)-2-((2-Aminoethoxy)carbamoyl)-7-oxo- 1,6-diazabicyclo(3.2.1)octan-6-yl hydrogen sulfate; (2S,5R)-2-(2-Aminoethoxycarbamoyl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulfate; (2S,5R)-N-(2-Aminoethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide; [(2S,5R)-2-(2-aminoethoxycarbamoyl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate; Sulfuric acid, mono((1R,2S,5R)-2-(((2-aminoethoxy)amino)carbonyl)-7-oxo-1,6-diazabicyclo(3.2.1)oct-6-yl) ester; Sulfuric acid, mono((1R,2S,5R)-2-(((2-aminoethoxy)amino)carbonyl)-7-oxo-1,6-diazabicyclo(3.2.1)oct-6-yl) ester, (-)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Bacterial infection [ICD-11: 1A00-1C4Z; ICD-10: A00-B99] | Phase 1 | [1] | |
| Company |
Meiji Seika Pharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C9H16N4O7S
|
|||
| Canonical SMILES |
C1CC(N2CC1N(C2=O)OS(=O)(=O)O)C(=O)NOCCN
|
|||
| InChI |
1S/C9H16N4O7S/c10-3-4-19-11-8(14)7-2-1-6-5-12(7)9(15)13(6)20-21(16,17)18/h6-7H,1-5,10H2,(H,11,14)(H,16,17,18)/t6-,7+/m1/s1
|
|||
| InChIKey |
RSBPYSTVZQAADE-RQJHMYQMSA-N
|
|||
| CAS Number |
CAS 1452458-86-4
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Staphylococcus Beta-lactamase (Stap-coc blaZ) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02134834) A Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of OP0595. U.S. National Institutes of Health. | |||
| REF 2 | OP0595, a new diazabicyclooctane: mode of action as a serine -lactamase inhibitor, antibiotic and -lactam 'enhancer'. J Antimicrob Chemother. 2015 Oct;70(10):2779-86. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.